Stoke Therapeutics, Inc. (STOK) Tops Q2 EPS by 10c

Stoke Therapeutics, Inc. (NASDAQ: STOK) reported Q2 EPS of ($0.40), $0.10 better than the analyst estimate of ($0.50). Revenue for the quarter came in at $13.82 million versus the consensus estimate of $9.39 million.

For earnings history and earnings-related data on Stoke Therapeutics, Inc. (STOK) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Palo Alto Networks (PANW) PT Raised to $400 at TD Cowen
• Oracle (ORCL) call put ratio 1.6 calls to 1 put with a focus on December 230 calls